Analyst Price Targets — MYGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 24, 2026 12:58 pm | Lu Li | UBS | $6.00 | $4.71 | TheFly | Myriad Genetics price target lowered to $6 from $8 at UBS |
| November 4, 2025 12:36 pm | Lu Li | UBS | $8.00 | $8.18 | TheFly | Myriad Genetics price target raised to $8 from $6 at UBS |
| May 7, 2025 1:14 pm | Bill Bonello | Craig-Hallum | $18.00 | $7.27 | TheFly | Myriad Genetics price target lowered to $18 from $29 at Craig-Hallum |
| May 7, 2025 12:18 pm | Lu Li | UBS | $7.00 | $7.27 | TheFly | Myriad Genetics price target lowered to $7 from $16 at UBS |
| May 7, 2025 10:45 am | Brandon Couillard | Wells Fargo | $6.00 | $7.27 | TheFly | Myriad Genetics downgraded to Equal Weight from Overweight at Wells Fargo |
| March 12, 2025 9:17 am | — | Piper Sandler | $12.50 | $10.41 | TheFly | Myriad Genetics upgraded to Overweight from Neutral at Piper Sandler |
| March 4, 2025 11:31 am | — | Piper Sandler | $11.50 | $10.42 | TheFly | Myriad Genetics price target lowered to $11.50 from $14 at Piper Sandler |
| December 9, 2024 11:07 am | Puneet Souda | Leerink Partners | $21.00 | $15.15 | StreetInsider | Leerink Partners Downgrades Myriad Genetics (MYGN) to Market Perform |
| October 14, 2024 10:25 am | Sung Ji Nam | Scotiabank | $34.00 | $24.67 | StreetInsider | Scotiabank Reiterates Sector Outperform Rating on Myriad Genetics (MYGN) |
| September 19, 2024 5:04 am | Tejas Savant | Morgan Stanley | $32.00 | $28.47 | TheFly | Myriad Genetics initiated with an Equal Weight at Morgan Stanley |
Latest News for MYGN
SALT LAKE CITY, April 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced that it will share six abstracts, including two podium presentations, at the American Association for Cancer Research (AACR) Annual Meeting 2026. "AACR is one of the premier forums for oncology research, and we are excited to share the depth of work…
SALT LAKE CITY, April 14, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the use of the MyChoice® Test for prostate cancer patients as a companion diagnostic for Lynparza® (olaparib). With this approval, clinicians can now order the MyChoice Test to…
SALT LAKE CITY, April 09, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that it will share new data at the Society of Gynecologic Oncology (SGO) Annual Meeting, including two oral presentations and two posters. “Having four abstracts accepted at the prestigious SGO annual meeting underscores the importance of the data…
Myriad Genetics, Inc. has grown from a mainly Hereditary Cancer business into a broader precision medicine company, but the market still values it at a low multiple because earnings, cash flow, and. The strongest part of the business is still the core Hereditary Cancer franchise, which has shown better resilience than other units through stronger volume trends and steadier operating performance. Even on a…
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MYGN.
U.S. House Trading
No House trades found for MYGN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.